0RK Stock Overview
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Exscientia plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.60 |
| 52 Week High | US$8.40 |
| 52 Week Low | US$3.62 |
| Beta | 0.78 |
| 1 Month Change | 4.55% |
| 3 Month Change | -23.33% |
| 1 Year Change | 0.88% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -75.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 21.1% | 2.1% | -1.0% |
| 1Y | 0.9% | -22.4% | 2.0% |
Return vs Industry: 0RK exceeded the German Biotechs industry which returned -21% over the past year.
Return vs Market: 0RK underperformed the German Market which returned 2.5% over the past year.
Price Volatility
| 0RK volatility | |
|---|---|
| 0RK Average Weekly Movement | 13.7% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0RK's share price has been volatile over the past 3 months.
Volatility Over Time: 0RK's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 483 | Dave Hallett | www.exscientia.ai |
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company’s lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies.
Exscientia plc Fundamentals Summary
| 0RK fundamental statistics | |
|---|---|
| Market cap | €597.51m |
| Earnings (TTM) | -€170.14m |
| Revenue (TTM) | €23.40m |
23.4x
P/S Ratio-3.2x
P/E RatioIs 0RK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RK income statement (TTM) | |
|---|---|
| Revenue | UK£20.08m |
| Cost of Revenue | UK£27.40m |
| Gross Profit | -UK£7.32m |
| Other Expenses | UK£138.64m |
| Earnings | -UK£145.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16 |
| Gross Margin | -36.48% |
| Net Profit Margin | -726.94% |
| Debt/Equity Ratio | 0.09% |
How did 0RK perform over the long term?
See historical performance and comparison